MHRA: IXCHIQ Vaccine UK Marketing Authorisation Withdrawn

• The MHRA has withdrawn the UK marketing authorisation for the IXCHIQ chikungunya vaccine due to an unfavorable benefit-risk balance.
• Serious adverse reactions, including chikungunya-like symptoms and rare neurological events, were reported, some leading to hospitalisation or death.
• Healthcare professionals must immediately cease prescribing, supplying, or administering IXCHIQ and dispose of existing stock.
• Individuals who experienced side effects after vaccination should seek medical advice and report to the Yellow Card scheme.
• Travelers to high-risk areas should consider alternative chikungunya prevention methods.

The MHRA's action stems from a determination that the vaccine's benefit-risk balance is no longer considered favorable for its intended use.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has announced the IXCHIQ vaccine UK marketing authorisation withdrawal, following a comprehensive safety review. This decision means the live attenuated vaccine, previously approved for preventing chikungunya virus infection in adults traveling to high-risk regions, can no longer be prescribed, supplied, or administered within the UK. The MHRA's action stems from a determination that the vaccine's benefit-risk balance is no longer considered favorable for its intended use.

This significant regulatory update, detailed in an MHRA Drug Safety Update from October 2026, necessitates immediate action from healthcare professionals. They are instructed to cease all use of the IXCHIQ vaccine and to dispose of any existing stock in accordance with established local policies. Instead, medical practitioners should guide individuals planning travel to chikungunya-prone areas towards alternative preventative measures, ensuring continued protection against the viral infection.

The MHRA IXCHIQ withdrawal was prompted by the emergence of serious adverse reactions reported since the vaccine's initial authorization. These adverse events included symptoms akin to chikungunya itself, alongside rare but severe neurological complications such as encephalitis. While these incidents were observed predominantly in older adults and individuals with pre-existing medical conditions, reports also indicated their occurrence in people with no known health issues. Tragically, some of these cases led to hospitalisation or even death.

The regulatory body undertook a thorough review of post-authorisation safety data, consulting closely with the Commission on Human Medicines (CHM). This expert advice was pivotal in concluding that the potential benefits of the IXCHIQ vaccine for UK travelers no longer outweighed the identified risks. This re-evaluation underscores the MHRA's commitment to Chikungunya vaccine safety UK and its proactive approach to drug safety monitoring, especially concerning IXCHIQ adverse events.

For individuals who have previously received the IXCHIQ vaccination without experiencing any side effects, the MHRA has clarified that there is no perceived risk, and no further medical intervention or revaccination is deemed necessary. However, anyone who experienced adverse reactions after receiving the IXCHIQ vaccine is strongly advised to seek medical consultation and to report their experience through the Yellow Card scheme IXCHIQ reporting system.

The Yellow Card scheme is a vital tool for ongoing drug safety surveillance, enabling healthcare professionals, patients, and caregivers to report suspected adverse drug reactions. Reports can be submitted electronically via the Yellow Card website, its dedicated app (available on Apple App Store and Google Play Store), or through various clinical IT systems used by healthcare professionals, including EMIS, SystmOne, Vision, MiDatabank, and Ulysses. When submitting a report, it is crucial to provide comprehensive details, such as medical history, any concomitant medications, the timing of symptom onset, and treatment dates, to aid in the thorough assessment of UK drug safety update IXCHIQ data.

Lawyers advising healthcare providers or pharmaceutical companies must ensure immediate compliance with the MHRA's withdrawal of the IXCHIQ vaccine marketing authorization, including cessation of prescription/administration, proper disposal of stock, and updating internal protocols. Compliance officers should review and update relevant policies and training to reflect the new safety profile and reporting requirements for adverse events.

Source: Original reporting via MHRA Drug Safety Update